These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16342656)

  • 21. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 22. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C; Castelli G; Crea F; Gavazzi A; Gensini GF; Scherillo M; Sinagra G
    G Ital Cardiol (Rome); 2012 Dec; 13(12):809-16. PubMed ID: 23196683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Yamamoto T
    Nihon Rinsho; 2007 May; 65 Suppl 5():102-6. PubMed ID: 17571373
    [No Abstract]   [Full Text] [Related]  

  • 26. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
    Coats AJ
    Int J Cardiol; 2001 Aug; 80(1):1-4. PubMed ID: 11532539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
    Martinez FA
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):345-50. PubMed ID: 20676926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 30. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone as a target in congestive heart failure.
    Rajagopalan S; Pitt B
    Med Clin North Am; 2003 Mar; 87(2):441-57. PubMed ID: 12693733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 35. [Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure].
    Tereshchenko SN; Zhirov IV; Osmolovskaia IuF
    Ter Arkh; 2013; 85(12):137-43. PubMed ID: 24640683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
    Deswal A; Richardson P; Bozkurt B; Mann DL
    J Card Fail; 2011 Aug; 17(8):634-42. PubMed ID: 21807324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor and cardiac arrhythmia.
    Gravez B; Tarjus A; Jaisser F
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.